First Patient Dosed in Phase 2a Trial of Nu-3 for Diabetic Foot Ulcers
LABT is trading near its 52-week low of $1.66 (8.4% above the low) on light trading volume (0.1× avg).
Summary
Lakewood-Amedex has dosed the first patient in its Phase 2a trial of Nu-3, a topical antimicrobial gel for mildly infected diabetic foot ulcers. This is the first clinical data milestone for the company's lead asset and validates the Bisphosphocin platform in humans. Topline data are expected in Q1 2027, providing a concrete near-term catalyst. The company has a market cap of only $4.2M and reported a $4.7M H1 net loss, so this trial is critical to its viability. The trial will evaluate three concentrations (2%, 5%, 10%) for safety and efficacy, with a Phase 2b study planned to follow.
At the time of this announcement, LABT was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.66 to $98.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.